By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has acquired certain assets from Perlegen Sciences, which ceased operations late last year.

Australia's Genetic Technologies said that the primary asset it has obtained is Perlegen's BrevaGen breast cancer risk test. In addition, it said that it acquired a suite of granted patents valid to 2022 that augment and extend its current non-coding patent portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.